NTRA — Natera, Inc. stock price, charts and financials

QT61Natera, Inc.

Natera, Inc. (NASDAQ: NTRA) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
270.36
+2.60+0.97%
NTRAQT61Natera, Inc.·NASDAQ
270.36+0.97%
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-1.63Insider Own3.55%Shs Outstand143.22MPerf Week2.20%
Market Cap38.35BForward P/E-EPS next Y-0.30Insider Trans-12.81%Shs Float136.90MPerf Month-3.08%
Enterprise Value37.50BPEG5.45EPS next Q-Inst Own-Short Float3.63%Perf Quarter29.88%
Income-230.08MP/S15.33EPS this Y0.76%Inst Trans-Short Ratio3.19Perf Half Y15.67%
Sales2.50BP/B21.36EPS next Y81.57%ROA-8.66%Short Interest4.96MPerf YTD16.88%
Book/sh-P/C179.55EPS next 5Y-ROE-15.13%52W High290.83 -7.04%Perf Year89.95%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-11.92%52W Low133.09 103.14%Perf 3Y468.25%
Dividend Est.-EV/EBITDA-Sales past 3/5Y41.15% 42.61%Gross Margin65.16%Volatility4.70% 3.99%Perf 5Y134.88%
Dividend TTM-EV/Sales14.99EPS Y/Y TTM-6.54%Oper. Margin-12.97%ATR (14)11.49Perf 10Y1978.88%
Dividend Ex-Date-Quick Ratio2.83Sales Y/Y TTM47.44%Profit Margin-9.05%RSI (14)55.94Recom2.11
Dividend Gr. 3/5Y-Current Ratio2.96EPS Q/Q-12.00%SMA20-0.42%Beta1.51Target Price274.45
Payout0.00%Debt/Eq0.14Sales Q/Q38.84%SMA509.41%Rel Volume0.89Prev Close267.76
Employees6,140LT Debt/Eq0.07EarningsAug 06SMA20021.40%Avg Volume1.50MPrice270.36
IPO DateJul 01, 2015Option/ShortYes / YesEPS/Sales Surpr.-3.28% 12.89%Net Debt/EBITDA3.79Volume1,331,254Change0.97%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-14-26ReiteratedCanaccord GenuityBuy$285$330
Jul-09-26ReiteratedMorgan StanleyOverweight$265$310
Jul-06-26ReiteratedEvercore ISI GroupOutperform$270$300
Jun-29-26ReiteratedGuggenheimBuy$270$290
Jun-24-26ReiteratedBTIGBuy$270$275
Jun-24-26ReiteratedUBSBuy$280$260
Jun-23-26ReiteratedBTIGBuy$125$270
Jun-11-26ReiteratedRBC CapitalOutperform$268$275
Jun-05-26DowngradeGoldman SachsBuyNeutral$80$245
May-12-26ReiteratedPiper SandlerOverweight$240$249
Latest News
Jul-26-26
Jul-25-26
Jul-22-26
Jul-21-26
Jul-20-26
Jul-18-26
Jul-16-26
Jul-14-26
Jul-10-26
Jul-09-26
Company

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,5022,3061,6971,083820625391302258
Cost of Goods Sold Incl. D&A872811674590456318204175166
Gross Profit1,6291,4951,02349336430718712792
Selling, General and Administrative Excl. Other1,2391,177841618589511304206155
Research and Development7056244043213162641005151
Other Operating Expense10400000-140
Operating Income-325-310-222-446-541-468-216-116-115
Interest Expense104111398151110
Unusual Expense
Non-Operating Income (Expense)494643244524-3
Net Income Before Taxes-286-268-190-435-547-471-230-123-128
Income Taxes-61-601011020
Consolidated Net Income-227-208-190-435-548-472-230-125-128
Net Income From Continuing Operations-227-208-190-435-548-472-230-125-128
Net Income-227-208-190-435-548-472-230-125-128
EPS (Recurring)-1.63-1.52-1.53-3.78-5.57-5.21-2.84-1.79-2.22
EPS (Basic, Before Extraordinaries)-1.63-1.52-1.53-3.78-5.57-5.21-2.84-1.79-2.22
EPS (Diluted)-1.63-1.52-1.53-3.78-5.57-5.21-2.84-1.79-2.22
EBITDA-223-221-148-383-507-452-206-104-107
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
Price To Sales Ratio15.3413.6111.666.654.8013.6020.627.813.14
Gross Margin65.1164.8360.2845.5244.3949.1247.8342.0535.66
Operating Margin-12.99-13.44-13.08-41.18-65.98-74.88-55.24-38.41-44.57
Net Margin-9.07-9.02-11.20-40.17-66.83-75.52-58.82-41.39-49.61
Shares Outstanding1421371251159891817058
Market Capitalization38,39131,38519,7887,2043,9378,4988,0612,358810
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$306.32$257.53$208.73$159.93$111.14 Close Price0.00M11.95M23.90M35.86M47.81MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Brophy Michael BurkesCHIEF FINANCIAL OFFICERJul 29 '26Sale249.381,863464,59552,432Jul 29
Sheena Jonathandirector, other: CO-FOUNDERJul 28 '26Sale254.0719148,527245,723Jul 29
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERJul 28 '26Sale254.071,003254,833170,407Jul 29
Fesko JohnPRESIDENT, CHIEF BUS. OFFICERJul 28 '26Sale254.07931236,540184,069Jul 29
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSJul 28 '26Sale254.071,204305,901132,429Jul 29
Chapman Steven LeonardCEO AND PRESIDENTJul 28 '26Sale254.073,580909,572102,973Jul 29
Brophy Michael BurkesCHIEF FINANCIAL OFFICERJul 28 '26Sale253.962,419614,33554,295Jul 29
Chapman Steven LeonardCEO AND PRESIDENTJul 27 '26Sale260.492,190570,475106,553Jul 29
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERJul 27 '26Sale260.49884230,274171,410Jul 29
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSJul 27 '26Sale260.491,010263,096133,633Jul 29
Brophy Michael BurkesCHIEF FINANCIAL OFFICERJul 27 '26Sale260.49782203,70456,714Jul 29
Sheena Jonathandirector, other: CO-FOUNDERJul 27 '26Sale260.4928875,021245,914Jul 29
Fesko JohnPRESIDENT, CHIEF BUS. OFFICERJul 27 '26Sale260.49782203,704185,000Jul 29
Rabinowitz MatthewEXECUTIVE CHAIRMANJul 27 '26Sale260.491,718447,5232,276,125Jul 29
Sheena Jonathandirector, other: CO-FOUNDERJul 15 '26Sale273.881,500410,82318,032Jul 17
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.